Strides Arcolab Ltd. said its wholly-owned subsidiary Onco Therapies Ltd. had obtained two more ANDA approvals from US FDA for Fludarabine Phosphate for Injection, USP packaged in 50mg/2 mL, single use vials (25 mg/mL upon reconstitution) - Lyophilized format and Idarubicin Hydrochloride Injection, 1mg/mL -5 mL and 20 mL single dose vials.
Fludarabine is a chemotherapy drug used to treat chronic Lymphocytic leukemia (a type of cancer of the while blood cells) in adults, while Idarubicin belongs to the group of cancer-fighting medications known as antineoplastics and is used alone or in combination with other antineoplastic medications to treat leukemia.
The combined market for the two drugs is around $20 million, the company said.
At the BSE, Strides Arcolab shares are currently trading at Rs.907.00, up 1.16 percent from the previous close.
For comments and feedback: editorial@rttnews.com